Durable responses in patients with HER2+ breast cancer and leptomeningeal metastases treated with trastuzumab deruxtecan
Laura Alder(Duke Medical Center), Sarah Sammons(Dana-Farber Cancer Institute), Carey K. Anders(Duke University), Christopher D. Lascola(Duke University), Liangge Hsu(Brigham and Women's Hospital), Dario Trapani(Harvard University), Nancy U. Lin(Dana-Farber Cancer Institute), Sara M. Tolaney(Harvard University), Mustafa Khasraw(Northwestern University), Claire Bradbury(Duke University), Amanda E.D. Van Swearingen(Duke Cancer Institute)
Cited by 50
Related Papers
Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment
|Cancer Discovery|2019|1.4k
Summary Report on the Graded Prognostic Assessment: An Accurate and Facile Diagnosis-Specific Tool to Estimate Survival for Patients With Brain Metastases
|Journal of Clinical Oncology|2011|1.4k
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
|Annals of Oncology|2021|1.4k
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
|New England Journal of Medicine|2019|1.3k
Response assessment criteria for brain metastases: proposal from the RANO group
|The Lancet Oncology|2015|1.1k